US11224630B2 - Medicinal composition for protection of joints, method for producing the same and use thereof - Google Patents
Medicinal composition for protection of joints, method for producing the same and use thereof Download PDFInfo
- Publication number
- US11224630B2 US11224630B2 US16/414,800 US201916414800A US11224630B2 US 11224630 B2 US11224630 B2 US 11224630B2 US 201916414800 A US201916414800 A US 201916414800A US 11224630 B2 US11224630 B2 US 11224630B2
- Authority
- US
- United States
- Prior art keywords
- extract
- parts
- group
- cartilage
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 210000000845 cartilage Anatomy 0.000 claims abstract description 92
- 206010003246 arthritis Diseases 0.000 claims abstract description 75
- 210000000582 semen Anatomy 0.000 claims abstract description 73
- 235000013305 food Nutrition 0.000 claims abstract description 34
- 230000003247 decreasing effect Effects 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- -1 effervescent Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 15
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 28
- 241000700159 Rattus Species 0.000 description 21
- 230000008961 swelling Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 10
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 10
- 102100030416 Stromelysin-1 Human genes 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 210000001179 synovial fluid Anatomy 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 210000000544 articulatio talocruralis Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 230000008355 cartilage degradation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
Definitions
- the present disclosure relates to the field of health care food technology, specifically to a traditional Chinese medicine composition for protecting joint, a use thereof, a method for producing the same and a health care food thereof.
- Osteoarthritis is a common chronic disease having characters of gradually losing articular cartilage, subchondral bone sclerosis and synovitis. Osteoarthritis of the knee is a clinical common degenerative joint disease, and the main clinical features are chronic pain of joint, swelling, stiffness at morning and even limited mobility, and joint deformity. The prevalence rate of middle-aged and elderly people is higher, women are more afflicted than men, and the incidence rate is gradually increasing with age. Osteoarthritis is a chronic, disabling disease.
- interleukin plays a considerable role in the pathological process of osteoarthritis of the knee, which is the main cause of articular cartilage degradation and synovial membrane inflammatory response.
- IL-1 interleukin-1
- IL-6 interleukin-6
- IL-7 interleukin-7
- IL-8 interleukin-17
- IL-18 may accelerate the damage of cartilage.
- other cytokines such as IL-4, IL-9, IL-10 and IL-13 may play positive roles to protect the cartilage from being damaged.
- IL-1 and TNF- ⁇ are important inflammatory cytokines of human body, which participates in the progressive damage of cartilage in pathology of osteoarthritis, so that changes the normal structure and function of cartilage cells, facilitating the generation and development of osteoarthritis in the knee.
- Factors that facilitate damage of the cartilage for example, chondrocyte apoptosis, degradation of cartilage cell matrix, synovial membrane inflammatory lesions and bone metabolism, include an internal path and an external path.
- the former is the degradation process of cartilage cells themselves, and the latter is the process of cartilage destruction by joint synovial fluid.
- enzymatic substances degrading the extracellular matrix play an important role in both paths.
- Matrix metalloproteinase 3 is a zinc ion-dependent enzyme, which has a main function of degrading extracellular matrix.
- MMP-3 may destroy and degrade proteoglycans, and cause the losing of small molecular proteoglycans, resulting in reduced cartilage elasticity and making the arched network structure loose, so that the stress capacity of cartilage is also reduced, and proteoglycan also has a relatively weak winding protective effect on type II collagen.
- COL-II is the main collagen component in articular cartilage, which ensures the integrity of the articular cartilage structure.
- Osteoarthritis of the knee is a category of “Bi disease” in traditional Chinese medicine.
- the main cause is Feng, cold, dampness and internal resistance, joint and main and collateral channels obstruction, resulting in poor circulation and dysfunction of Qi and blood.
- understanding and treatment of Osteoarthritis of the knee has a long history.
- the Yellow Emperor's Classic of Internal Medicine has the discussion of “the liver works on tendons, and the kidney works on bones”. Kidney is the origin of congenital constitution, stores essential substances and works on bones.
- the bone marrow will be deficient, osteoporosis occurs, Qi and blood will be deficiency, tendons and bones will be dystrophic, easy to be affected by the exogenous pathogens and develops to a Bi disease in the knee.
- Bi disease obstacles the tendons and bones, muscles, joints, leading to poor Qi and blood circulation, and the obstacle results in pain.
- cartilage extract CURCUMAE LONGAE RHIZOMA, COICIS SEMEN and PUERARIAE LOBATAE RADIX together to make a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
- the present disclosure provides a Chines medicine composition for protecting the joint, a use thereof, a method for producing the same and a health care food thereof.
- the traditional Chinese medicine composition has functions of synergistically reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
- the present disclosure provides following technical solutions.
- the present disclosure provides a traditional Chinese medicine composition with a function of protecting joints, comprising CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
- active ingredients such as CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract are used to prepare the composition.
- CURCUMAE LONGAE RHIZOMA may dredge the blood vessels and promote the circulation of Qi, induce menstruation to relieve menalgia, and can be used for treating thoracic tingling, amenorrhea and dysmenorrhea, rheumatism and brachialgia, abdominal mass, and swelling caused by tumble.
- CURCUMAE LONGAE RHIZOMA is used in treating osteoarthritis of the knee, the effects on relieving pain and anti-inflammation are remarkable, and the safety is high and side effects are few.
- the component curcumin may also improve the symptoms of Osteoarthritis of the knee by affecting FLs, cytokines (TNF- ⁇ , IL-1, VEGF), metalloproteinases (MMP-1, 13), and signal pathways of NF-KB.
- Cartilage extract comprises active ingredients such as collagen, chondroitin sulfate and hyaluronic acid, etc., which may inhibit the growth of abnormally proliferating blood vessels, reconstruct articular cartilage, and inhibit cartilage degradation.
- active ingredients such as collagen, chondroitin sulfate and hyaluronic acid, etc.
- the combination of the two can synergistically improve the symptoms of osteoarthritis of the knee, achieving the effect of preventing Osteoarthritis of the knee. Symptoms such as joint pain, swelling, stiffness, abnormal sound, etc. are relieved.
- COICIS SEMEN nourishes the spleen and removes the humidification, and the main and collateral channels are unobstructed after dehumidification.
- COICIS SEMEN comprises coixenolide and coixol.
- COICIS SEMEN has functions of analgesia and reducing the inflammatory response of body.
- COICIS SEMEN may reduce the expression of VEGF-A.
- COICIS SEMEN effective extract obviously inhibits the expression of HIF-1 ⁇ , so that inhibits the expression of MVD in synovial membrane vessels and reduce synovial membrane angiogenesis.
- PUERARIAE LOBATAE RADIX has effects of expelling pathogenic factors from muscles for abatement of heat, promoting the secretion of body liquid, promoting eruption, arising yang and antidiarrheal.
- Puerarin contained in the PUERARIAE LOBATAE RADIX may relieve articular swelling, improve microcirculation and resist vasospasm, improving the hypercoagulability of blood vessel, so as to achieve the effect of treating arthritis.
- CURCUMAE LONGAE RHIZOMA extract cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract are used to produce a composition which can synergistically reduce arthrocele degree, decrease arthritis index, ameliorate physiological index of arthritis and reduce articular cavity area through various pathways and at various levels.
- the traditional Chinese medicine composition comprises parts by weight: 1 ⁇ 20 parts of CURCUMAE LONGAE RHIZOMA extract, 20 ⁇ 40 parts of cartilage extract, 1 ⁇ 20 parts of COICIS SEMEN extract, and 0.1 ⁇ 1.0 part of PUERARIAE LOBATAE RADIX extract.
- the traditional Chinese medicine composition comprises parts by weight: 5 ⁇ 10 parts of CURCUMAE LONGAE RHIZOMA extract, 25 ⁇ 35 parts of cartilage extract, 5 ⁇ 15 parts of COICIS SEMEN extract, and 0.1 ⁇ 0.5 part of PUERARIAE LOBATAE RADIX extract.
- the traditional Chinese medicine composition comprises parts by weight: 10 parts of CURCUMAE LONGAE RHIZOMA extract, 35 parts of cartilage extract, 15 parts of COICIS SEMEN extract, and 0.5 part of PUERARIAE LOBATAE RADIX extract.
- the traditional Chinese medicine composition comprises parts by weight: 5 parts of CURCUMAE LONGAE RHIZOMA extract, 25 parts of cartilage extract, 5 parts of COICIS SEMEN extract, and 0.1 part of PUERARIAE LOBATAE RADIX extract.
- the traditional Chinese medicine composition comprises parts by weight: 8 parts of CURCUMAE LONGAE RHIZOMA extract, 30 parts of cartilage extract, 10 parts of COICIS SEMEN extract, and 0.3 part of PUERARIAE LOBATAE RADIX extract.
- the relieving arthritis is one or more effects selected from reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
- a method for producing the traditional Chinese medicine composition comprising mixing CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
- a health care food comprising the traditional Chinese medicine composition.
- the traditional Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
- the health care food further comprises a food additive.
- the dosage form of the health care food is oral liquid, capsule, tablet, powder, effervescent, granule or tableted candy.
- a traditional Chinese medicine composition with a function of protecting joints, a use thereof, a method for producing the same and a health care food thereof is provided.
- the traditional Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
- the present disclosure has the following technical effects.
- compositions for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area mainly comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract, and the composition is used to prepare health care foods having functions of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
- composition of the present invention various ingredients are rationally formulated and cooperate with each other to achieve effects of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area through multiple ways and at various levels.
- results show that the composition of the present disclosure has functions of relieving arthrocele and lowering arthritis index, indicating that combining CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract together has a synergistic effect.
- Osteoarthritis of the knee is closely related to IL-1 ⁇ , IL-6 and TNF- ⁇ in the blood, PGE2 and IL-1 ⁇ in the tissue, and MMP-3 and COL-II in the synovial fluid, etc.
- the contents of interleukin 1 ⁇ , interleukin 5 and tumor necrosis factor ⁇ in the serum, matrix metalloproteinase-3 and type II collagen in the synovial fluid, prostaglandin and interleukin-1 ⁇ in the swollen tissue, and articular cavity can be improved by the composition of the present disclosure.
- using CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract together has a synergistic effect.
- COICIS SEMEN nourishes the spleen and removes the humidification.
- the effective ingredient of COICIS SEMEN, coix seed oil, has effects of anti-inflammation and relieving pain, and effectively remits the inflammatory responses.
- PUERARIAE LOBATAE RADIX has functions of expelling pathogenic factors from muscles for abatement of heat, promoting the secretion of body liquid, promoting eruption, arising yang and antidiarrheal.
- the neovascularization factor contained in cartilage inhibits the growth of abnormally proliferating blood vessels, reconstructs articular cartilage, and inhibits cartilage degradation.
- a combination of CURCUMAE LONGAE RHIZOMA, COICIS SEMEN, PUERARIAE LOBATAE RADIX and cartilage extract has a synergistic function of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
- a composition was obtained by mixing CURCUMAE LONGAE RHIZOMA extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and cartilage extract, all were purchased on the market or hand-made. All the raw materials or adjuvants used in the traditional Chinese medicine composition and the use thereof, the method for producing the same and the health care food thereof provided by the present disclosure were purchased from the market.
- CURCUMAE LONGAE RHIZOMA extract was purchased from CHR Hansen (China) Co., Ltd.; COICIS SEMEN extract was purchased from Shaanxi Jiahe Phytochem Co., Ltd; PUERARIAE LOBATAE RADIX extract was purchased from Huangshan greenxtract Biotechnology Co., Ltd., cartilage extract was purchased from Meitek Technology (Qingdao) Co., Ltd.
- the cartilage extract was purchased from the market, or hand-made, and the extraction method was: pre-treatment, enzymatic hydrolysis, impurity removal, drying and the like.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract were weighed according to the weight ratio, other adjuvants and water were added. After processes of preparation, encapsulation, sterilization, etc., an oral liquid was obtained, which could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and other adjuvants were weighed. After sieving, mixing, and packing, a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained.
- the dosage form of the composition was powder, and the powders could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, tableting, etc. to obtain tablets or tableted candies.
- the tablets or tableted candies could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, and filling to obtain the composition in a dosage form of hard capsule, which could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, and filling to obtain the composition in a dosage form of soft capsule, which could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, granulating, drying and packing to obtain the composition in a dosage form of granule, which could be used as a health care food or food.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, encapsulating, sterilizing and other process to obtain the composition in a dosage form of oral liquid.
- a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was made from the following active ingredients in parts by weight:
- composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, encapsulating, sterilizing and other process to obtain the composition in a dosage form of oral liquid.
- the health care food or food of the present disclosure composition obtained in Example 2 (a formulation for relieving arthritis), provided by Infinitus (China) Co., Ltd., which was yellow powders.
- the recommended oral administration amount of human being was 1.56 g/day, once a day; body weight of each person was set as 60 kg, so the equivalent dose of the composition was 0.026 g/kg ⁇ bw.
- the daily administration amount of cartilage extract was 1 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 0.0167 g/kg ⁇ bw.
- the daily administration amount of CURCUMAE LONGAE RHIZOMA extract was 0.2 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 3.333 mg/kg ⁇ bw.
- the daily administration amount of COICIS SEMEN extract was 0.2 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 3.333 mg/kg ⁇ bw.
- administration amount of rat in the formula group was 0.26 g/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 1.56 g/day;
- administration amount of rat in the cartilage extract group was 166.67 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 1 g/day;
- administration amount of rat in the CURCUMAE LONGAE RHIZOMA extract group was 33.33 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 0.2 g/day;
- administration amount of rat in the COICIS SEMEN extract group was 33.33 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 0.2 g/day.
- the administration amount of (cartilage extract+CURCUMAE LONGAE RHIZOMA extract) group was a combination of 166.67 mg/kg cartilage extract and 33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract.
- the administration amount of (cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract) group was a combination of 166.67 mg/kg cartilage extract, 33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract and 33.33 mg/kg COICIS SEMEN extract.
- the samples of each dosage group were fine milled, and distilled water was added and the resultant was blended and adjusted to a constant volume suitable for gavage administration.
- Grouping SD rats, female, SPF grade, 180 ⁇ 220 g, were purchased from Experimental Animal Center of Sun Yat-sen University. The rats were randomly divided into 8 groups, 10 rats per group.
- A. normal control group B. model group, C. cartilage extract group (166.67 mg/kg), D. CURCUMAE LONGAE RHIZOMA extract group (33.33 mg/kg), E. COICIS SEMEN extract group (33.33 mg/kg), F. cartilage extract+CURCUMAE LONGAE RHIZOMA extract group (166.67 mg/kg cartilage extract+33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract), G.
- cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group (166.67 mg/kg cartilage extract+33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract+33.33 mg/kg COICIS SEMEN extract), and H. formula group (0.26 g/kg).
- AI Arthritis index
- test data was analyzed by GraphPad Prism 7.0 biological statistical software.
- the data was expressed as Mean ⁇ SD; weight, arthritis index, arthrocele degree was analyzed by one-way ANOVA combining with Dunnett's multiple comparisons; and biochemical indicators, articular cavity were analyzed by one-way analysis of variance.
- the arthrocele degree of the model groups significantly increased (P ⁇ 0.01), wherein the arthrocele degree of the 3 th day after model establishment was the highest. After 3 d, the arthrocele gradually reduced, and tended to be stable after 14 d of model establishment. Comparing with the model group, test samples reduced the arthrocele degree in varying degrees, wherein the effects of cartilage extract+CURCUMAE LONGAE RHIZOMA extract group, cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group showed significant difference (P ⁇ 0.05 or P ⁇ 0.01), and the formula group was the optimum (see Table 4).
- Biochemical indicators in serum comparing with the normal group, contents of IL-1 ⁇ , IL-6 and TNF- ⁇ in the serum of the model group significantly increased (P ⁇ 0.01). Comparing with the model group, each test sample has effect of reducing contents of IL-1 ⁇ , IL-6 and TNF- ⁇ in the serum at certain degree, wherein the cartilage extract+CURCUMAE LONGAE RHIZOMA extract group, cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group significantly decreased the contents of IL-1 ⁇ , IL-6 and TNF- ⁇ in the serum (P ⁇ 0.05 or P ⁇ 0.01). Results are shown in Table 5.
- Biochemical indicator of swelling tissue comparing with the normal group, contents of PGE2 and IL-1 ⁇ in the swelling tissue of the model group significantly increased (P ⁇ 0.01). Comparing with the model group, each test sample has effect of reducing contents of PGE2 and IL-1 ⁇ in the tissue at certain degree, wherein the cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group significantly decreased the content of PGE2 in the tissue (P ⁇ 0.05 or P ⁇ 0.01); and the formula group also reduced the content IL-1 in the tissue (see Table 6).
- Biochemical indicators of synovial fluid comparing with the normal group, content of MMP-3 in the synovial fluid of the swelling tissue of the model groups significantly increased (P ⁇ 0.01).
- each test sample has effect of reducing content of MMP-3 in the tissue at certain degree, wherein the formula group showed the most significant effect (P ⁇ 0.05). Comparing with the normal group, content of COL-II in the synovial fluid of the swelling tissue of the model group significantly decreased (P ⁇ 0.01). Comparing with the model group, each test sample has effect of increasing content of COL-II in the synovial fluid at certain degree, but the difference is not significant (P>0.05). Results are shown in Table 7.
- composition of the present disclosure has functions of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area, and can be used for manufacturing health care foods or foods for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
Abstract
The present invention relates to the field of health care food technology, specifically to a traditional Chinese medicine composition with a function of protecting joints, a use thereof, a method for producing the same and a health care food thereof. The Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract. The composition of the present disclosure has a reasonable formulation, and the ingredients cooperate with each other to achieve functions of reducing arthrocele degree, decreasing arthritis index, ameliorating biochemical index of arthritis and reducing articular cavity area through various paths and at various levels.
Description
This application claims the priority of Chinese Patent Application No. 201811600951.7, filed on Dec. 26, 2018, and the disclosures of which are hereby incorporated by reference.
The present disclosure relates to the field of health care food technology, specifically to a traditional Chinese medicine composition for protecting joint, a use thereof, a method for producing the same and a health care food thereof.
Osteoarthritis (OA) is a common chronic disease having characters of gradually losing articular cartilage, subchondral bone sclerosis and synovitis. Osteoarthritis of the knee is a clinical common degenerative joint disease, and the main clinical features are chronic pain of joint, swelling, stiffness at morning and even limited mobility, and joint deformity. The prevalence rate of middle-aged and elderly people is higher, women are more afflicted than men, and the incidence rate is gradually increasing with age. Osteoarthritis is a chronic, disabling disease.
Researches have shown that interleukin (IL) plays a considerable role in the pathological process of osteoarthritis of the knee, which is the main cause of articular cartilage degradation and synovial membrane inflammatory response. For example, all of IL-1, IL-6, IL-7, IL-8, IL-17 and IL-18 may accelerate the damage of cartilage. However, other cytokines such as IL-4, IL-9, IL-10 and IL-13 may play positive roles to protect the cartilage from being damaged. IL-1 and TNF-α are important inflammatory cytokines of human body, which participates in the progressive damage of cartilage in pathology of osteoarthritis, so that changes the normal structure and function of cartilage cells, facilitating the generation and development of osteoarthritis in the knee. Factors that facilitate damage of the cartilage, for example, chondrocyte apoptosis, degradation of cartilage cell matrix, synovial membrane inflammatory lesions and bone metabolism, include an internal path and an external path. The former is the degradation process of cartilage cells themselves, and the latter is the process of cartilage destruction by joint synovial fluid. And enzymatic substances degrading the extracellular matrix play an important role in both paths. Matrix metalloproteinase 3 (MMP-3) is a zinc ion-dependent enzyme, which has a main function of degrading extracellular matrix. In the early period of osteoarthritis, MMP-3 may destroy and degrade proteoglycans, and cause the losing of small molecular proteoglycans, resulting in reduced cartilage elasticity and making the arched network structure loose, so that the stress capacity of cartilage is also reduced, and proteoglycan also has a relatively weak winding protective effect on type II collagen. COL-II is the main collagen component in articular cartilage, which ensures the integrity of the articular cartilage structure.
Osteoarthritis of the knee is a category of “Bi disease” in traditional Chinese medicine. The main cause is Feng, cold, dampness and internal resistance, joint and main and collateral channels obstruction, resulting in poor circulation and dysfunction of Qi and blood. In traditional Chinese medicine, understanding and treatment of Osteoarthritis of the knee has a long history. The Yellow Emperor's Classic of Internal Medicine has the discussion of “the liver works on tendons, and the kidney works on bones”. Kidney is the origin of congenital constitution, stores essential substances and works on bones. If deficiency of the kidney occurs, the bone marrow will be deficient, osteoporosis occurs, Qi and blood will be deficiency, tendons and bones will be dystrophic, easy to be affected by the exogenous pathogens and develops to a Bi disease in the knee. Bi disease obstacles the tendons and bones, muscles, joints, leading to poor Qi and blood circulation, and the obstacle results in pain.
At present, no one has combined cartilage extract, CURCUMAE LONGAE RHIZOMA, COICIS SEMEN and PUERARIAE LOBATAE RADIX together to make a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
In view of this, the present disclosure provides a Chines medicine composition for protecting the joint, a use thereof, a method for producing the same and a health care food thereof. The traditional Chinese medicine composition has functions of synergistically reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
In order to achieve the above object of the disclosure, the present disclosure provides following technical solutions.
The present disclosure provides a traditional Chinese medicine composition with a function of protecting joints, comprising CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
In the present disclosure, active ingredients such as CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract are used to prepare the composition.
CURCUMAE LONGAE RHIZOMA may dredge the blood vessels and promote the circulation of Qi, induce menstruation to relieve menalgia, and can be used for treating thoracic tingling, amenorrhea and dysmenorrhea, rheumatism and brachialgia, abdominal mass, and swelling caused by tumble. When CURCUMAE LONGAE RHIZOMA is used in treating osteoarthritis of the knee, the effects on relieving pain and anti-inflammation are remarkable, and the safety is high and side effects are few. Therein, the component curcumin may also improve the symptoms of Osteoarthritis of the knee by affecting FLs, cytokines (TNF-α, IL-1, VEGF), metalloproteinases (MMP-1, 13), and signal pathways of NF-KB.
Cartilage extract comprises active ingredients such as collagen, chondroitin sulfate and hyaluronic acid, etc., which may inhibit the growth of abnormally proliferating blood vessels, reconstruct articular cartilage, and inhibit cartilage degradation. The combination of the two can synergistically improve the symptoms of osteoarthritis of the knee, achieving the effect of preventing Osteoarthritis of the knee. Symptoms such as joint pain, swelling, stiffness, abnormal sound, etc. are relieved.
COICIS SEMEN nourishes the spleen and removes the humidification, and the main and collateral channels are unobstructed after dehumidification. COICIS SEMEN comprises coixenolide and coixol. COICIS SEMEN has functions of analgesia and reducing the inflammatory response of body. At the same time, COICIS SEMEN may reduce the expression of VEGF-A. COICIS SEMEN effective extract obviously inhibits the expression of HIF-1α, so that inhibits the expression of MVD in synovial membrane vessels and reduce synovial membrane angiogenesis.
PUERARIAE LOBATAE RADIX has effects of expelling pathogenic factors from muscles for abatement of heat, promoting the secretion of body liquid, promoting eruption, arising yang and antidiarrheal. Puerarin contained in the PUERARIAE LOBATAE RADIX may relieve articular swelling, improve microcirculation and resist vasospasm, improving the hypercoagulability of blood vessel, so as to achieve the effect of treating arthritis.
Thus, in the present disclosure, CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract are used to produce a composition which can synergistically reduce arthrocele degree, decrease arthritis index, ameliorate physiological index of arthritis and reduce articular cavity area through various pathways and at various levels.
Preferably, the traditional Chinese medicine composition comprises parts by weight: 1˜20 parts of CURCUMAE LONGAE RHIZOMA extract, 20˜40 parts of cartilage extract, 1˜20 parts of COICIS SEMEN extract, and 0.1˜1.0 part of PUERARIAE LOBATAE RADIX extract.
Preferably, the traditional Chinese medicine composition comprises parts by weight: 5˜10 parts of CURCUMAE LONGAE RHIZOMA extract, 25˜35 parts of cartilage extract, 5˜15 parts of COICIS SEMEN extract, and 0.1˜0.5 part of PUERARIAE LOBATAE RADIX extract.
More preferably, the traditional Chinese medicine composition comprises parts by weight: 10 parts of CURCUMAE LONGAE RHIZOMA extract, 35 parts of cartilage extract, 15 parts of COICIS SEMEN extract, and 0.5 part of PUERARIAE LOBATAE RADIX extract.
In one specific embodiment provided in the present disclosure, the traditional Chinese medicine composition comprises parts by weight: 5 parts of CURCUMAE LONGAE RHIZOMA extract, 25 parts of cartilage extract, 5 parts of COICIS SEMEN extract, and 0.1 part of PUERARIAE LOBATAE RADIX extract.
In another specific embodiment provided in the present disclosure, the traditional Chinese medicine composition comprises parts by weight: 8 parts of CURCUMAE LONGAE RHIZOMA extract, 30 parts of cartilage extract, 10 parts of COICIS SEMEN extract, and 0.3 part of PUERARIAE LOBATAE RADIX extract.
In the present disclosure, a use of the traditional Chinese medicine composition in manufacturing a health care food for relieving arthritis is also provided.
In the present disclosure, the relieving arthritis is one or more effects selected from reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
In the present disclosure, a method for producing the traditional Chinese medicine composition is also provided, comprising mixing CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
In the present disclosure, a health care food comprising the traditional Chinese medicine composition is also provided. The traditional Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract.
Preferably, the health care food further comprises a food additive.
Preferably, the dosage form of the health care food is oral liquid, capsule, tablet, powder, effervescent, granule or tableted candy.
In the present disclosure, a traditional Chinese medicine composition with a function of protecting joints, a use thereof, a method for producing the same and a health care food thereof is provided. The traditional Chinese medicine composition comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract. The present disclosure has the following technical effects.
(1) In the present disclosure, a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area is provided. The composition mainly comprises CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract, and the composition is used to prepare health care foods having functions of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
(2) In the composition of the present invention, various ingredients are rationally formulated and cooperate with each other to achieve effects of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area through multiple ways and at various levels.
(3) In the present disclosure, results show that the composition of the present disclosure has functions of relieving arthrocele and lowering arthritis index, indicating that combining CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract together has a synergistic effect.
(4) Osteoarthritis of the knee is closely related to IL-1β, IL-6 and TNF-α in the blood, PGE2 and IL-1β in the tissue, and MMP-3 and COL-II in the synovial fluid, etc. In the present disclosure, the contents of interleukin 1β, interleukin 5 and tumor necrosis factor α in the serum, matrix metalloproteinase-3 and type II collagen in the synovial fluid, prostaglandin and interleukin-1β in the swollen tissue, and articular cavity can be improved by the composition of the present disclosure. Especially, using CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract together has a synergistic effect.
In the present disclosure, a traditional Chinese medicine composition for protecting joint, a use thereof, a method for producing the same and a health care food thereof is provided. One of ordinary skill in the art can learn from the contents of this document and appropriately improve the process parameters to achieve the disclosure. It is should be noted that all such alternatives and modifications are obvious to one of ordinary skill in the art and are considered to be included in the present invention. The method and application of the present disclosure have been described in terms of preferred embodiments. It will be apparent to one of ordinary skill in the art that the methods and applications described herein may be modified or modified and combined to implement and practice the techniques of the present disclosure without departing from the spirit and scope of protection of the present disclosure.
In TCM Disease Diagnosis and Treatment Terminology-Diseases, Osteoarthritis of the knee is specifically called “Bi in the knee”. Blood stasis leads to Bi disease, and long-time Bi disease certainly leads to stagnate of blood, thus eliminating blood stasis is necessary in treating Bi disease. Traditional Chinese medicine CURCUMAE LONGAE RHIZOMA is one of the medicines for invigorating blood circulation and eliminating stasis, which is the dry rhizome of zingiberaceae Curcuma Longa L. or Curcuma rcenyujin Y, H. Chenet C. Ling. It is pungent and bitter in taste and warm in nature, works on the spleen and liver channel, having functions of dredging the blood vessels and promoting the circulation of Qi. The traditional Chinese medicine thinks that weakness of the spleen and the stomach, unbalance diet may lead to poor yield of Qi and blood, lack of muscles, and malnutrition of joints in arms and legs. If the above conditions last long, Qi and blood is depletion, bones and tendons and the blood vessels are not nourished, the nutrient qi and defensive qi camp is out of harmony, the pathogen of the Feng, cold and dampness invades and effects on the tendon and vessel, resulting in the rheumatism and Bi disease. COICIS SEMEN nourishes the spleen and removes the humidification. The effective ingredient of COICIS SEMEN, coix seed oil, has effects of anti-inflammation and relieving pain, and effectively remits the inflammatory responses. PUERARIAE LOBATAE RADIX has functions of expelling pathogenic factors from muscles for abatement of heat, promoting the secretion of body liquid, promoting eruption, arising yang and antidiarrheal. The neovascularization factor contained in cartilage inhibits the growth of abnormally proliferating blood vessels, reconstructs articular cartilage, and inhibits cartilage degradation. A combination of CURCUMAE LONGAE RHIZOMA, COICIS SEMEN, PUERARIAE LOBATAE RADIX and cartilage extract has a synergistic function of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
In the present disclosure, a composition was obtained by mixing CURCUMAE LONGAE RHIZOMA extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and cartilage extract, all were purchased on the market or hand-made. All the raw materials or adjuvants used in the traditional Chinese medicine composition and the use thereof, the method for producing the same and the health care food thereof provided by the present disclosure were purchased from the market. CURCUMAE LONGAE RHIZOMA extract was purchased from CHR Hansen (China) Co., Ltd.; COICIS SEMEN extract was purchased from Shaanxi Jiahe Phytochem Co., Ltd; PUERARIAE LOBATAE RADIX extract was purchased from Huangshan greenxtract Biotechnology Co., Ltd., cartilage extract was purchased from Meitek Technology (Qingdao) Co., Ltd.
In the present disclosure, the cartilage extract was purchased from the market, or hand-made, and the extraction method was: pre-treatment, enzymatic hydrolysis, impurity removal, drying and the like.
The present disclosure will be further illustrated in conjunction with examples hereinafter.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract and PUERARIAE LOBATAE RADIX extract were weighed according to the weight ratio, other adjuvants and water were added. After processes of preparation, encapsulation, sterilization, etc., an oral liquid was obtained, which could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and other adjuvants were weighed. After sieving, mixing, and packing, a composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained. The dosage form of the composition was powder, and the powders could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, tableting, etc. to obtain tablets or tableted candies. The tablets or tableted candies could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, and filling to obtain the composition in a dosage form of hard capsule, which could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, and filling to obtain the composition in a dosage form of soft capsule, which could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 10 parts, cartilage extract 35 parts, COICIS SEMEN extract 15 parts, PUERARIAE LOBATAE RADIX extract 0.5 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to sieving, mixing, granulating, drying and packing to obtain the composition in a dosage form of granule, which could be used as a health care food or food.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 5 parts, cartilage extract 25 parts, COICIS SEMEN extract 5 parts, PUERARIAE LOBATAE RADIX extract 0.1 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, encapsulating, sterilizing and other process to obtain the composition in a dosage form of oral liquid.
A composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area provided by the present disclosure was made from the following active ingredients in parts by weight:
CURCUMAE LONGAE RHIZOMA extract 8 parts, cartilage extract 30 parts, COICIS SEMEN extract 10 parts, PUERARIAE LOBATAE RADIX extract 0.3 part.
The composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area was obtained by the following method: CURCUMAE LONGAE RHIZOMA extract, cartilage extract, COICIS SEMEN extract, PUERARIAE LOBATAE RADIX extract and regular adjuvants were taken and subjected to mixing, encapsulating, sterilizing and other process to obtain the composition in a dosage form of oral liquid.
Pharmacodynamics research on composition for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area
1. Test Agency
Laboratory of Pharmacology and Toxicology, School of Pharmacy, Sun Yat-sen University.
2. Purpose of the Test
To study whether the health care food or food of the present disclosure has functions of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
3. Materials
The health care food or food of the present disclosure: composition obtained in Example 2 (a formulation for relieving arthritis), provided by Infinitus (China) Co., Ltd., which was yellow powders. The recommended oral administration amount of human being was 1.56 g/day, once a day; body weight of each person was set as 60 kg, so the equivalent dose of the composition was 0.026 g/kg·bw. The daily administration amount of cartilage extract was 1 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 0.0167 g/kg·bw. The daily administration amount of CURCUMAE LONGAE RHIZOMA extract was 0.2 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 3.333 mg/kg·bw. The daily administration amount of COICIS SEMEN extract was 0.2 g/day; body weight of each person was set as 60 kg, so the equivalent dose was 3.333 mg/kg·bw.
4. Method (Efficacy Study in Animal)
4.1 Design of the Dosage
| TABLE 1 |
| Administration amount according to body weight |
| Multiples amounting | ||
| Group | to human dosage | Dosage for rat |
| Cartilage extract | 10 | 166.67 | mg/kg |
| CURCUMAE LONGAE | 10 | 33.33 | mg/kg |
| RHIZOMA extract | |||
| COICIS SEMEN | 10 | 33.33 | mg/kg |
| extract |
| Cartilage extract + | 10 | 166.67 mg/kg cartilage extract |
| CURCUMAE LONGAE | and 33.33 mg/kg CURCUMAE | |
| RHIZOMA extract | LONGAE RHIZOMA extract | |
| Cartilage extract + | 10 | 166.67 mg/kg cartilage extract, |
| CURCUMAE LONGAE | 33.33 mg/kg CURCUMAE LONGAE | |
| RHIZOMA extract + | RHIZOMA extract and 33.33 mg/kg | |
| COICIS SEMEN extract | COICIS SEMEN extract |
| Example 2 | 10 | 0.26 | g/kg |
The dosage design: administration amount of rat in the formula group was 0.26 g/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 1.56 g/day;
administration amount of rat in the cartilage extract group was 166.67 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 1 g/day;
administration amount of rat in the CURCUMAE LONGAE RHIZOMA extract group was 33.33 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 0.2 g/day;
administration amount of rat in the COICIS SEMEN extract group was 33.33 mg/kg, equal to 10 multiples of the administration amount of a 60 kg-adult, 0.2 g/day.
The administration amount of (cartilage extract+CURCUMAE LONGAE RHIZOMA extract) group was a combination of 166.67 mg/kg cartilage extract and 33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract.
The administration amount of (cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract) group was a combination of 166.67 mg/kg cartilage extract, 33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract and 33.33 mg/kg COICIS SEMEN extract.
The samples of each dosage group were fine milled, and distilled water was added and the resultant was blended and adjusted to a constant volume suitable for gavage administration.
Grouping: SD rats, female, SPF grade, 180˜220 g, were purchased from Experimental Animal Center of Sun Yat-sen University. The rats were randomly divided into 8 groups, 10 rats per group. A. normal control group, B. model group, C. cartilage extract group (166.67 mg/kg), D. CURCUMAE LONGAE RHIZOMA extract group (33.33 mg/kg), E. COICIS SEMEN extract group (33.33 mg/kg), F. cartilage extract+CURCUMAE LONGAE RHIZOMA extract group (166.67 mg/kg cartilage extract+33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract), G. cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group (166.67 mg/kg cartilage extract+33.33 mg/kg CURCUMAE LONGAE RHIZOMA extract+33.33 mg/kg COICIS SEMEN extract), and H. formula group (0.26 g/kg).
4.2 Effects on Adjuvant-Induced Arthritis Rat Model
SD rats of each group were preventively administered for 2 weeks, once a day. 2 weeks after the administration, 0.1 mL Freund's complete adjuvant was injected to right back vola pedis of rats to induce inflammation. On the same day, all the groups were administered, and continuously administered once a day for 3 weeks. After the administration, samples were collected and the following indexes were detected.
1) Observation: mental states of rats, walking, etc., were observed every day; and the body weight was weighed every 7 d.
2) Arthritis index (AI): arthritic index was evaluated by arthritis scoring method (0˜4 grades). 0 point: normal, without arthritis; 1 point: erythema and slight swelling occurred on the ankle joint; 2 points: erythema and slight swelling occurred from the ankle joint to the metatarsophalangeal joint or the palm joint; 3 points: erythema and moderate swelling occurs from the ankle joint to the metatarsophalangeal joint or palm joint; 4 points: erythema and severe swelling occurs from the ankle joint to the metatarsophalangeal joint.
3) Measure of arthrocele: the volume of vola pedis was measured by the vola pedis volume measuring instrument once before the inflammation and 3 h, 3 d, 7 d, 14 d, 21 d, 30 d after the inducing of inflammation, and the difference in volume of the vola pedis before and after was used to evaluate the arthrocele degree.
4) Measure of biochemical indicators: blood sample was collected, and serum was separated to measure the contents of IL-1β, IL-6 and TNF-α by ELISA; synovial fluid was collected to measure the expression levels of MMP-3 and COL-II; and the inflammatory swelling paw was sheared off, and levels of prostaglandin PGE2 and IL-1β were measured.
5) Measure of articular cavity: after anesthesia, the ankle joint was irradiated with an ultrasound apparatus to measure the area of articular cavity of the ankle joint.
4.3 Statistics Analysis
The test data was analyzed by GraphPad Prism 7.0 biological statistical software. The data was expressed as Mean±SD; weight, arthritis index, arthrocele degree was analyzed by one-way ANOVA combining with Dunnett's multiple comparisons; and biochemical indicators, articular cavity were analyzed by one-way analysis of variance.
5. Test Result
5.1 Observation
1 h after model establishment in rat, all the model rats showed claudication. 3 h later, the inflammatory paw swelled. 18 h later, the swelling reached the peak value. 3 d later, the swelling gradually reduced, and tended to back to normal after 14 d.
Before the administration and 1 to 14 d of the preventive administration, there was no statistical difference in body weight between each group (P>0.05); 14 d after the administration, except for the normal group, all other groups were subjected to model establishment. Comparing with the normal group, from the 21th day of administration (the 7th day of model establishment), body weight of each modeled group tended to reduce; on the 28th day of administration (the 14th day of model establishment) and the 35th day of administration (the 21th day of model establishment), the body weight of modeled group showed significantly reduced (P<0.01). Comparing with the model group, test samples have no obvious effect on weight of the rats (P>0.05). Results are shown in Table 2.
| TABLE 2 |
| Effects of the composition on weight of Freund's adjuvant-induced arthritis model rats (g, Mean ± SD) |
| 0 d of the | 7 d of the | 14 d of the | 21 d of the | 28 d of the | 35 d of the | |
| Group | administration | administration | administration | administration | administration | administration |
| A. normal group | 207.50 ± 11.54 | 222.20 ± 7.70 | 233.70 ± 12.34 | 233.30 ± 18.34 | 252.50 ± 11.16** | 279.00 ± 16.65** |
| B. model group | 208.40 ± 12.78 | 214.20 ± 15.30 | 224.40 ± 12.94 | 227.20 ± 16.80 | 232.50 ± 15.69 | 252.40 ± 26.30 |
| C. Cartilage extract | 206.40 ± 9.35 | 213.10 ± 11.93 | 224.80 ± 14.13 | 224.00 ± 8.47 | 232.10 ± 10.57 | 253.60 ± 17.95 |
| group | ||||||
| D. CURCUMAE | 206.50 ± 9.92 | 218.60 ± 9.61 | 231.60 ± 11.23 | 226.80 ± 15.66 | 235.60 ± 15.94 | 260.50 ± 13.67 |
| LONGAE RHIZOMA | ||||||
| extract group | ||||||
| E. COICIS SEMEN | 208.40 ± 9.25 | 219.70 ± 11.96 | 237.80 ± 18.02 | 235.30 ± 17.63 | 238.10 ± 11.92 | 257.30 ± 11.26 |
| extract group | ||||||
| F. Cartilage extract + | 208.10 ± 10.35 | 220.00 ± 12.65 | 233.80 ± 13.10 | 233.40 ± 14.03 | 245.10 ± 12.91 | 260.10 ± 14.81 |
| CURCUMAE LONGAE | ||||||
| RHIZOMA extract group | ||||||
| G. Cartilage extract + | 207.70 ± 7.53 | 220.40 ± 8.69 | 230.40 ± 10.56 | 234.40 ± 7.72 | 243.60 ± 14.71 | 256.50 ± 13.07 |
| CURCUMAE LONGAE | ||||||
| RHIZOMA extract + | ||||||
| COICIS SEMEN extract | ||||||
| group | ||||||
| H. formula group | 208.00 ± 10.90 | 223.80 ± 10.45 | 231.00 ± 7.94 | 234.70 ± 9.57 | 242.00 ± 14.52 | 258.20 ± 13.23 |
| (Example 2) | ||||||
| Comment: comparing with the model group, | ||||||
| *P < 0.05; and | ||||||
| **P < 0.01. | ||||||
Comment: comparing with the model group, *: P<0.05; and **: P<0.01.
5.2 Arthritis Index
Comparing with the normal group, AI scores of the model group increased significantly (P<0.01), wherein the score of the 3th day after model establishment was the highest. After 3 d, the scores gradually reduced, and tended to be stable after 14 d of model establishment. Comparing with the model group, each group improved the AI score in varying degrees. In the test drugs, effects of the cartilage extract+CURCUMAE LONGAE RHIZOMA group, cartilage extract+CURCUMAE LONGAE RHIZOMA+COICIS SEMEN group and the formula group were the most significant (P<0.05 or P<0.01); and wherein the formula group was the optimum (reference was made to Table 3).
| TABLE 3 |
| Effects of the composition on arthritis index of Freund's adjuvant-induced arthritis model rats (g, Mean ± SD) |
| 3 h after model | 3 d after model | 7 d after model | 14 d after model | 21 d after model | |
| Group | establishment | establishment | establishment | establishment | establishment |
| A. normal group | 0.00 ± 0.00** | 0.00 ± 0.00** | 0.00 ± 0.00** | 0.00 ± 0.00** | 0.00 ± 0.00** |
| B. model group | 3.30 ± 0.67 | 3.90 ± 0.32 | 3.40 ± 0.52 | 3.20 ± 0.42 | 3.10 ± 0.74 |
| C. Cartilage extract | 3.00 ± 0.47 | 3.60 ± 0.52 | 3.10 ± 0.57 | 2.80 ± 0.42 | 2.70 ± 0.67 |
| group | |||||
| D. CURCUMAE | 3.20 ± 0.63 | 3.80 ± 0.42 | 3.20 ± 0.42 | 2.90 ± 0.57 | 2.80 ± 0.79 |
| LONGAE | |||||
| RHIZOMA extract | |||||
| group | |||||
| E. COICIS SEMEN | 3.10 ± 0.32 | 3.60 ± 0.70 | 3.00 ± 0.47 | 2.70 ± 0.67 | 2.60 ± 0.70 |
| extract group | |||||
| F. Cartilage extract + | 2.80 ± 0.42 | 3.40 ± 0.70 | 2.70 ± 0.48* | 2.50 ± 0.53* | 2.50 ± 0.53 |
| CURCUMAE LONGAE | |||||
| RHIZOMA extract | |||||
| group | |||||
| G. Cartilage extract + | 2.70 ± 0.48 | 3.30 ± 0.48 | 2.50 ± 0.53** | 2.40 ± 0.52** | 2.40 ± 0.84* |
| CURCUMAE LONGAE | |||||
| RHIZOMA extract + | |||||
| COICIS SEMEN | |||||
| extract group | |||||
| H. formula group | 2.60 ± 0.52* | 3.00 ± 0.82** | 2.60 ± 0.70** | 2.40 ± 0.52** | 2.30 ± 0.48** |
| (Example 2) | |||||
| Comment: comparing with the model group, | |||||
| *P < 0.05; and | |||||
| **P < 0.01 | |||||
5.3 Arthrocele Degree
Comparing with the normal group, the arthrocele degree of the model groups significantly increased (P<0.01), wherein the arthrocele degree of the 3th day after model establishment was the highest. After 3 d, the arthrocele gradually reduced, and tended to be stable after 14 d of model establishment. Comparing with the model group, test samples reduced the arthrocele degree in varying degrees, wherein the effects of cartilage extract+CURCUMAE LONGAE RHIZOMA extract group, cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group showed significant difference (P<0.05 or P<0.01), and the formula group was the optimum (see Table 4).
| TABLE 4 |
| Effects of the composition on arthrocele degree of Freund's adjuvant-induced arthritis model rats (g, Mean ± SD) |
| 3 h after model | 3 d after model | 7 d after model | 14 d after model | 21 d after model | |
| Group | establishment | establishment | establishment | establishment | establishment |
| A. normal group | 0.03 ± 0.15** | 0.04 ± 0.16** | 0.09 ± 0.12** | 0.11 ± 0.14** | 0.13 ± 0.11** |
| B. model group | 1.36 ± 0.29 | 2.39 ± 0.56 | 2.04 ± 1.07 | 1.66 ± 0.39 | 1.61 ± 0.32 |
| C. cartilage extract | 1.37 ± 0.25 | 2.34 ± 0.69 | 1.89 ± 0.36 | 1.59 ± 0.60 | 1.51 ± 0.25 |
| group | |||||
| D. CURCUMAE | 1.37 ± 0.29 | 2.31 ± 0.49 | 1.65 ± 0.27 | 1.44 ± 0.30 | 1.39 ± 0.33 |
| LONGAE | |||||
| RHIZOMA extract | |||||
| group | |||||
| E. COICIS SEMEN | 1.35 ± 0.28 | 2.28 ± 0.55 | 1.72 ± 0.33 | 1.49 ± 0.21 | 1.46 ± 0.40 |
| extract group | |||||
| F. cartilage extract + | 1.28 ± 0.23 | 2.13 ± 0.46 | 1.55 ± 0.39* | 1.32 ± 0.21 | 1.25 ± 0.25 |
| CURCUMAELONGAE | |||||
| RHIZOMA extract | |||||
| group | |||||
| G. cartilage extract + | 1.26 ± 0.24 | 2.07 ± 0.44 | 1.48 ± 0.25** | 1.22 ± 0.28 | 1.19 ± 0.25 |
| CURCUMAE LONGAE | |||||
| RHIZOMA extract + | |||||
| COICIS SEMEN | |||||
| extract group | |||||
| H. formula group | 1.21 ± 0.21 | 1.95 ± 0.47 | 1.34 ± 0.29** | 1.22 ± 0.33* | 1.13 ± 0.20* |
| (Example 2) | |||||
| Comment: comparing with the model group, | |||||
| *P < 0.05; and | |||||
| **P < 0.01 | |||||
5.4 Measure of Biochemical Indicators
Biochemical indicators in serum: comparing with the normal group, contents of IL-1β, IL-6 and TNF-α in the serum of the model group significantly increased (P<0.01). Comparing with the model group, each test sample has effect of reducing contents of IL-1β, IL-6 and TNF-α in the serum at certain degree, wherein the cartilage extract+CURCUMAE LONGAE RHIZOMA extract group, cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group significantly decreased the contents of IL-1β, IL-6 and TNF-α in the serum (P<0.05 or P<0.01). Results are shown in Table 5. Biochemical indicator of swelling tissue: comparing with the normal group, contents of PGE2 and IL-1β in the swelling tissue of the model group significantly increased (P<0.01). Comparing with the model group, each test sample has effect of reducing contents of PGE2 and IL-1β in the tissue at certain degree, wherein the cartilage extract+CURCUMAE LONGAE RHIZOMA extract+COICIS SEMEN extract group and the formula group significantly decreased the content of PGE2 in the tissue (P<0.05 or P<0.01); and the formula group also reduced the content IL-1 in the tissue (see Table 6). Biochemical indicators of synovial fluid: comparing with the normal group, content of MMP-3 in the synovial fluid of the swelling tissue of the model groups significantly increased (P<0.01). Comparing with the model group, each test sample has effect of reducing content of MMP-3 in the tissue at certain degree, wherein the formula group showed the most significant effect (P<0.05). Comparing with the normal group, content of COL-II in the synovial fluid of the swelling tissue of the model group significantly decreased (P<0.01). Comparing with the model group, each test sample has effect of increasing content of COL-II in the synovial fluid at certain degree, but the difference is not significant (P>0.05). Results are shown in Table 7.
| TABLE 5 |
| Effects of the composition on biochemical indicators in serum of Freund's |
| adjuvant-induced arthritis model rats (Mean ± SD) |
| Group | IL-1β (pg/mL) | IL-6 (pg/mL) | TNF-α (pg/mL) |
| A. normal group | 113.42 ± 25.97** | 787.25 ± 120.12** | 78.35 ± 10.39** |
| B. model group | 509.61 ± 16.47 | 1579.92 ± 71.57 | 253.40 ± 19.00 |
| C. cartilage extract group | 487.01 ± 60.36 | 1471.27 ± 166.23 | 235.47 ± 36.05 |
| D. CURCUMAE LONGAE | 441.68 ± 76.07 | 1417.31 ± 132.32 | 218.08 ± 40.74 |
| RHIZOMA extract group | |||
| E. COICIS SEMEN extract | 472.17 ± 62.03 | 1531.38 ± 152.87 | 231.85 ± 32.36 |
| group | |||
| F. cartilage extract + | 422.82 ± 82.72* | 1404.23 ± 162.10* | 217.24 ± 31.33* |
| CURCUMAE LONGAE | |||
| RHIZOMA extract group | |||
| G. cartilage extract + | 410.20 ± 83.09* | 1374.56 ± 147.16* | 209.11 ± 27.76** |
| CURCUMAE LONGAE | |||
| RHIZOMA extract + COICIS | |||
| SEMEN extract group | |||
| H. formula group (Example 2) | 387.14 ± 83.28** | 1232.20 ± 157.22** | 191.03 ± 32.30** |
| TABLE 6 |
| Effects of the composition on biochemical indicators of swelling foot tissue |
| of Freund's adjuvant-induced arthritis model rats (Mean ± SD) |
| Group | PGE2 (pg/mg) | IL-1β (pg/mg) |
| A. normal group | 199.94 ± 23.66** | 311.00 ± 88.03** |
| B. model group | 429.96 ± 39.00 | 686.49 ± 79.44 |
| C. cartilage extract group | 412.73 ± 30.86 | 619.06 ± 89.78 |
| D. CURCUMAE LONGAE | 391.80 ± 31.18 | 608.43 ± 77.55 |
| RHIZOMA extract group | ||
| E. COICIS SEMEN group | 397.58 ± 43.74 | 652.18 ± 75.30 |
| F. Cartilage extract + | 384.29 ± 40.37 | 608.90 ± 89.27 |
| CURCUMAE LONGAE RHIZOMA | ||
| extract group | ||
| G. Cartilage extract + | 381.80 ± 34.49* | 593.43 ± 66.62 |
| CURCUMAE LONGAE | ||
| RHIZOMA extract + | ||
| COICIS SEMEN extract group | ||
| H. formula group (Example 2) | 364.07 ± 61.21** | 572.85 ± 93.98* |
| TABLE 7 |
| Effects of the composition on MMP-3, COL- II in synovial fluid of Freund's |
| adjuvant-induced arthritis model rats (Mean ± SD) |
| Group | MMP-3 (pg/mL) | COL-II (pg/mL) |
| A. normal group | 91.92 ± 20.91** | 371.70 ± 46.45** |
| B. model group | 244.11 ± 32.26 | 199.45 ± 36.25 |
| C. cartilage extract group | 228.43 ± 38.93 | 216.62 ± 47.77 |
| D. CURCUMAE LONGAE | 216.16 ± 32.47 | 231.31 ± 59.35 |
| RHIZOMA extract group | ||
| E. COICIS SEMEN extract group | 223.80 ± 46.51 | 222.56 ± 34.22 |
| F. cartilage extract + | 213.36 ± 45.26 | 236.89 ± 52.20 |
| CURCUMAE LONGAE | ||
| RHIZOMA extract group | ||
| G. cartilage extract + | 200.46 ± 42.33 | 237.04 ± 74.52 |
| CURCUMAE LONGAE | ||
| RHIZOMA extract + | ||
| COICIS SEMEN extract | ||
| group | ||
| H. formula group (Example 2) | 192.83 ± 30.52* | 245.93 ± 39.54 |
| Comment: comparing with the model group, | ||
| *P < 0.05; and | ||
| **P < 0.01 | ||
5.5 Measure of Articular Cavity
Comparing with the normal group, the articular cavity area of ankle joint of the model group significantly increased (P<0.01). Comparing with the model group, each test sample has effect of reducing articular cavity area of the ankle joint at certain degrees, where in the effect of the formula group was the most significant (P<0.05). Results are shown in Table 8.
| TABLE 8 |
| Effects of the composition on articular cavity area of ankle of Freund's |
| 2 adjuvant-induced arthritis model rats (mm2, Mean ± SD) |
| articular cavity | |
| Group | (mm2) |
| A. normal group | 20.76 ± 3.10** |
| B. model group | 40.32 ± 4.17 |
| C. cartilage extract group | 37.32 ± 9.57 |
| D. CURCUMAE LONGAE RHIZOMA group | 35.43 ± 5.33 |
| E. COICIS SEMEN group | 37.73 ± 8.90 |
| F. Cartilage extract + CURCUMAE | 34.36 ± 5.83 |
| LONGAE RHIZOMA group | |
| G. Cartilage extract + CURCUMAE LONGAE | 33.21 ± 7.27 |
| RHIZOMA + COICIS SEMEN group | |
| H. formula group (Example 2) | 31.15 ± 5.67* |
| Comment: comparing with the model group, | |
| *P < 0.05; and | |
| **P < 0.01. | |
Thus, the composition of the present disclosure has functions of reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area, and can be used for manufacturing health care foods or foods for reducing arthrocele degree, decreasing arthritis index, ameliorating physiological index of arthritis and reducing articular cavity area.
The above descriptions are only preferred embodiments of the present disclosure. It should be noted that a number of modifications and refinements may be made by one or ordinary skill in the art without departing from the principles of the disclosure, and such modifications and refinements are also considered to be within the scope of protection of the disclosure.
Claims (8)
1. A medicine composition with a function of protecting joints, comprising parts by weight: 5 to 10 parts of Curcumae longae rhizome extract, 25 to 35 parts of cartilage extract, 5 to 15 parts of Coicis semen extract and 0.1 to 0.5 parts of Puerariae lobatae radix extract.
2. The medicine composition according to claim 1 , comprising parts by weight: 10 parts of Curcumae longae rhizome extract, 35 parts of cartilage extract, 15 parts of Coicis semen extract, and 0.5 parts of Puerariae lobatae radix extract.
3. The medicine composition according to claim 1 , which is in a form of a health care food.
4. The medicine composition according to claim 3 , wherein dosage form of the health care food is oral liquid, capsule, tablet, powder, effervescent, granule or tableted candy.
5. The medicine composition according to claim 3 , wherein the health care food further comprises a food additive.
6. A method of producing the medicine composition according to claim 1 , comprising mixing parts by weight: 5 to 10 parts of Curcumae longae rhizome extract, 25 to 35 parts of cartilage extract, 5 to 15 parts of Coicis semen extract and 0.1 to 0.5 parts of Puerariae lobatae radix extract.
7. A method of relieving arthritis, comprising administering an effective amount of the composition according to claim 1 to a subject in need thereof.
8. The method according to claim 7 , wherein the relieving arthritis is one or more selected from reducing arthrocele degree, decreasing arthritis index, ameliorating biochemical index of arthritis and reducing articular cavity area.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811600951.7 | 2018-12-26 | ||
| CN201811600951.7A CN109453342A (en) | 2018-12-26 | 2018-12-26 | A kind of Chinese medicine composition and application, preparation method, health food with joint protection effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20200206296A1 US20200206296A1 (en) | 2020-07-02 |
| US11224630B2 true US11224630B2 (en) | 2022-01-18 |
Family
ID=65614619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/414,800 Active 2039-05-18 US11224630B2 (en) | 2018-12-26 | 2019-05-17 | Medicinal composition for protection of joints, method for producing the same and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US11224630B2 (en) |
| CN (1) | CN109453342A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771741A (en) * | 2019-11-11 | 2020-02-11 | 深圳市红瑞生物科技有限公司 | Composition, preparation method and application thereof in preparation of joint care medicines, health-care products and foods |
| CN113117041B (en) * | 2021-05-12 | 2022-04-19 | 陈永 | Yin-nourishing traditional Chinese medicine composition containing liquorice and dandelion and application thereof |
| CN114903961A (en) * | 2022-05-16 | 2022-08-16 | 大闽食品（漳州）有限公司 | Composition for treating osteoarthropathy and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037903A1 (en) * | 2001-06-13 | 2004-02-26 | Lemmo Edward A. | Phytonutrient formula for the relief of chronic pain resulting from inflammation |
| CN103623006A (en) | 2013-11-26 | 2014-03-12 | 青岛贝尔特生物科技有限公司 | Production method of fish cartilage extract for preventing and treating osteoarthritis |
| US20140212519A1 (en) * | 2013-01-30 | 2014-07-31 | Infinitus (China) Company Ltd. | Chinese herbal medicine composition having a function of reducing uric acid |
-
2018
- 2018-12-26 CN CN201811600951.7A patent/CN109453342A/en active Pending
-
2019
- 2019-05-17 US US16/414,800 patent/US11224630B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037903A1 (en) * | 2001-06-13 | 2004-02-26 | Lemmo Edward A. | Phytonutrient formula for the relief of chronic pain resulting from inflammation |
| US20140212519A1 (en) * | 2013-01-30 | 2014-07-31 | Infinitus (China) Company Ltd. | Chinese herbal medicine composition having a function of reducing uric acid |
| CN103623006A (en) | 2013-11-26 | 2014-03-12 | 青岛贝尔特生物科技有限公司 | Production method of fish cartilage extract for preventing and treating osteoarthritis |
Non-Patent Citations (3)
| Title |
|---|
| Li Jiren et al., Theory of Li Jiren's arthralgia syndrome, 1st Ed., Oct. 31, 2011, Coix seed, 1-10, pp. 114-115, People's Medical Publishing House. |
| The 1st Office Action dated Nov. 24, 2020 regarding Chinese Patent Application No. CN201811600951.7. |
| Tian Yan, Chinese Medicine for Intractable Diseases, 2nd edition, Henan Science and Technology Press, Jan. 31, 2018, Radix Puerariae, pp. 147-149. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200206296A1 (en) | 2020-07-02 |
| CN109453342A (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11224630B2 (en) | Medicinal composition for protection of joints, method for producing the same and use thereof | |
| US10286021B2 (en) | Composition for prevention or treatment of arthritis, containing Sargassum serratifolium extract as active ingredient | |
| CN104758404B (en) | A kind of three snake compound powder of compound and preparation method thereof | |
| CN100372559C (en) | Traditional Chinese emdicine compounding prepns. for treating fracture | |
| KR101740028B1 (en) | Composition for preventing, improving, or treating arthritis comprising Achyranthis Japonicae Radix and Scutellariae Radix or Achyranthis Japonicae Radix, Scutellariae Radix and Acanthopanacis Cortex | |
| CN101406688A (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| KR101727132B1 (en) | Composition for preventing or treating of Henoch-Schonlein Purpura | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| KR101463091B1 (en) | Composition comprising the purified fraction isolated from bee venom for preventing and treating a joint disease comprising a cervical and lumbar disc or inflammatory disease and manufacturing method thereof | |
| KR102087338B1 (en) | Functional food for preventing or improving osteoarthritis containing an extract of Angelica gigas Nakai | |
| CN110876796B (en) | Traditional Chinese medicine composition for treating acute gout attack and preparation method and application thereof | |
| CN110478416B (en) | Composition for treating rheumatic and rheumatoid arthritis and preparation method and application thereof | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN111569005A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| WO2019244087A1 (en) | Composition for use in the prevention and/or treatment of osteoarticular diseases | |
| CN110893206B (en) | Externally applied medicine for treating rheumatic arthritis and preparation method thereof | |
| CN103638233B (en) | A kind of Chinese medicine composition for the treatment of flaming up of stomach-fire type periodontitis | |
| CN1528436A (en) | Chinese medicine preparation using rhizoma gastrodiae and eucommia as main material and preparing method thereof | |
| CN108144026B (en) | Pharmaceutical composition for treating osteoarthritis | |
| CN105641586A (en) | Fengtongning preparation and preparation method thereof | |
| Agrawal et al. | CRITICAL REVIEW OF KALKA KALPANA (AN AYURVEDIC DOSAGE FORM) FROM SUSHRUTA SAMHITA | |
| CN117959400A (en) | Traditional Chinese medicine composition, pharmaceutical preparation and application thereof in preparation of medicine for treating spleen-kidney yang deficiency type obesity | |
| Zhou et al. | Effects of fumigation and washing with Shujin Huoluo decoction combined with Duhuo Parasitic decoction on TIMP-1 and PON1 levels in KOA patients. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: INFINITUS (CHINA) COMPANY LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, LIUGANG;YUE, ZHONGBAO;HE, DANLIN;AND OTHERS;REEL/FRAME:049216/0556 Effective date: 20190509 |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |